Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

被引：87

作者：

Choi, Michael Y. ^{[1
]}

Widhof, George F., II ^{[1
]}

Wu, Christina C. N. ^{[1
]}

Cui, Bing ^{[1
]}

Lao, Fitzgerald ^{[1
]}

Sadarangani, Anil ^{[1
,2
]}

Cavagnaro, Joy ^{[3
]}

Prussak, Charles ^{[1
]}

Carson, Dennis A. ^{[1
]}

Jamieson, Catriona ^{[1
,2
]}

Kipps, Thomas J. ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA

[2] Univ Calif San Diego, Div Regenerat Med, La Jolla, CA 92093 USA

[3] Access Bio, Boyce, VA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷

基金：

美国国家卫生研究院;

关键词：

AKT; cancer stem cell; Cirmtuzumab; CLL; Wnt receptor; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN ROR1; EXPRESSION; RECEPTOR; PSEUDOKINASE; PHENOTYPE; FAMILY; CLL;

D O I：

10.1016/j.clml.2015.02.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL. (C) 2015 The Authors. Published by Elsevier Inc.

引用

页码：S167 / S169

页数：3

共 50 条

[41] First-in-class monoclonal antibody (mAb) PBP1510 targeting pancreatic adenocarcinoma upregulated factor (PAUF) for pancreatic cancer (PC) treatment: Preclinical perspectives.
Mandakhalikar, Kedar Diwakar
Koh, Sang Seok
Jeong, Seong-Yun
Moshinsky, Deborah
Feyaerts, Peggy
Karuna, Ratna
Kim, Jamie
Jaison, Litha
Pradhan, Sumita
Kim, Yeon Jeong
Park, Jin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16274 - E16274
[42] BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADC
Hao, Xiaoyao
Li, Hongyan
Liu, Xiaodong F.
Liu, Jinyu
Dai, Wenwen
Pan, Ying
Hu, Hui-Han
Li, Jun
Xia, Shukai
Lyu, Qun
Davis, Hugh M.
Chen, Mingjiu
Peng, Zeyu
CANCER RESEARCH, 2024, 84 (06)
[43] Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Mahalingam, Devalingam
Wang, Judy S.
Hamilton, Erika P.
Sarantopoulos, John
Nemunaitis, John
Weems, Garry
Carter, Laura
Hu, Xiao
Schreeder, Marshall
Wilkins, H. Jeffrey
CLINICAL CANCER RESEARCH, 2019, 25 (12) : 3508 - 3516
[44] On-going phase 1A clinical trial for AG01 an first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies
Tkaczuk, Katherine R.
Rosenblatt, Paula
Mehra, Ranee
Scilla, Katherine A.
Tait, Nancy
Caple, Katerra
Yue, Binbin
Serrero, Ginette
CANCER RESEARCH, 2023, 83 (08)
[45] A first-in-class bispecific antibody- drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1
Zhang, Yifu
Shang, Chenzhang
Wang, Nannan
An, Gao
Zhang, Ellen
Lin, Qingcong
Yang, Yi
CANCER RESEARCH, 2023, 83 (08)
[46] Anti-conformation monoclonal antibody effective in pre-clinical treatment of full Alzheimer's disease animal models by targeting pathological oligomeric forms of Aβ and modified Tau
Goni, F.
Marta-Ariza, M.
Herline, K.
Boutajangout, A.
Mehta, P.
Drummond, E.
Prelli, F.
Wisniewski, T.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 1035 - 1035
[47] PRE-CLINICAL STUDIES TO ADVANCE ZILOVERTAMAB-BASED ANTI-ROR1 DUAL SPECIFICITY CAR T-CELL THERAPY FOR METASTATIC PROSTATE CANCER.
Jamieson, Christina
Murtadha, Jamillah
Oh, Christopher S.
Muldong, Michelle
Koutouan, Evodie
Kim, JongWook
Etemadfard, Niloofar
Choo, Hae Soo
Sinha, Navyaa
Pineda, Gabriel
Lennon, Kathleen
Wu, Christina N.
Kipps, Thomas J.
Jamieson, Catriona
Kane, Christopher
Mckay, Rana
Gaasterland, Terry
Kulidjian, Anna
Prussak, Charles
Cacalano, Nicholas
JOURNAL OF UROLOGY, 2023, 209 : E146 - E146
[48] Safety and Efficacy of First-in-Class mtROS scavenger SkQ1 for the Treatment of Dry Eye Disease: A Phase 3 Clinical Trial
Friedhoff, Lawrence Tim
Petrov, Anton
Ousler, George W.
Watson, Michael
Xue, Qi
Ngiam, Malcolm
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
[49] Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers
Hernandez, Genevive
Bilic, Sanela
Guan, Yinghui
So, John
Bhattacharya, Sabya
Wang, Beatrice
Kotturi, Maya
Oyasu, Miho
Desbois, Melanie
Cao, Yuan
Humke, Eric
Ahern, Sean
Sinclair, Angus
Ulahannan, Susanna
Subbiah, Vivek
Pelster, Merideth
Lorusso, Patricia
Falchook, Gerald
Wang, Judy
Barve, Minal
Grewal, Jaspreet
Chow, Warren
Henry, Jason
Cecchini, Michael
Takimoto, Chris
Leabman, Maya
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[50] Pre-clinical toxicology and safety of SH7139: The first of a new class of targeted therapeutics for non-Hodgkin's lymphoma and other cancers
Balhorn, Rod
Balhorn, Monique Cosman
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →